Why Did Insmed Stock Jump?
Savara Inc. SVRA
$4.89
▼ -3.17%
($-0.16)
🔥 High Short Interest
📅 Earnings This Week
Open
$5.05
Prev Close
$5.05
Day Range
$4.84 – $5.16
52W Range
$3.86 – $7.01
Market Cap
$1.04B
Beta
0.27
EPS (TTM)
$-0.58
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2001-06-25 |
| Shares Out. | 205,460,000 |
| Website | savarapharma.com/ ↗ |
| Phone | 15126141848 |
| Employees | 70 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$40.2M |
| Free Cash Flow | -$110.7M |
| Total Assets | $192.1M |
| Total Liabilities | $48.5M |
| Equity | $143.7M |
About Savara Inc.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Savara Inc. is a publicly traded company under the ticker symbol SVRA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
15 analysts (2026-11-01)